Vulvar cancer is a relatively rare gynaecological malignancy, the treatment of which is associated with significant patient morbidity. With reports that the incidence of vulvar cancer is increasing, there is a rising need for improved preventive, diagnostic and therapeutic tools. Recent advances within genetics and epigenetics present possible approaches for addressing this need, by contributing to the clarification of the aetiology of this disease, identifying screening and drug targets and introducing the potential for personalised treatments. This paper reviews the genetic and epigenetic research undertaken to date within vulvar cancer, evaluates its potential for clinical application and identifies directions for future research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajo.12241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion.
Int J Gynaecol Obstet
December 2024
Department of Gynecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna, Austria.
Many clinicians recommend that patients diagnosed with HPV-related gynecologic cancers receive prophylactic HPV vaccination at the time of cancer diagnosis or after cancer treatment. In view of the large use of such practice, we aimed to assess the literature evidence supporting the use of prophylactic HPV vaccines after diagnosis or treatment of HPV-related gynecologic cancers. Women who develop HPV-related cervical, vaginal, and vulvar cancers represent a subgroup of patients who may be particularly sensitive to HPV infection and re-acquire infections.
View Article and Find Full Text PDFBARRIERS TO PRESCRIPTION OF HORMONAL CONTRACEPTION AND HORMONE REPLACEMENT THERAPY IN GYNECOLOGICAL CANCER SURVIVORS: RESULTS OF A SURVEY AND LITERATURE REVIEW.
J Gynecol Obstet Hum Reprod
December 2024
Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal; Portuguese Gynecologic Oncology Section of the Portuguese Society of Gynecology. Electronic address:
Background: The incidence of gynecological cancers in premenopausal women is increasing, highlighting issues related to Hormonal Contraception (HC) and Hormone Replacement Therapy (HRT). However, the presence of hormonal receptors in many gynecological cancers complicates HC and HRT prescriptions.
Objective: To identify barriers experienced by gynecologists in prescribing HC and HRT to gynecological cancer survivors, with a secondary objective of conducting a literature review on the safety of these prescriptions.
Claudins in vulvar cancer - from epithelial barrier to potential tumor-agnostic cancer therapy.
Tissue Barriers
December 2024
Department of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.
The immunohistochemical expression of various members of the claudin family has already been studied in pathological affections of the vulva whether to differentiate precancerous lesions from vulvar squamous cell carcinoma or in inflammatory conditions such as lichen sclerosus. From an oncological perspective, however, immunohistochemical analysis of claudin 18.2 protein expression has become increasingly clinically relevant nowadays since the impressive therapeutic benefits of the claudin 18.
View Article and Find Full Text PDFSuccessful Management of HPV-Associated Vulvar Cancer During Pregnancy: A Case Report and Treatment Approach.
Am J Case Rep
December 2024
Surgical Gynecology Clinic of The Gynecological and Obstetrics Clinical Hospital, Poznań University of Medical Sciences, Poznań, Poland.
BACKGROUND Human Papilloma Virus (HPV)-associated Vulvar Squamous Cell Carcinomas (VSCC) present more frequently in young women than HPV- independent tumors. Due to its association with HPV infection, the incidence of vulvar cancer is increasing in young women; however, during pregnancy, it is still extremely rare. CASE REPORT We present the case of a 36-year-old pregnant woman at 23 weeks of pregnancy, diagnosed with HPV 16-associated VSCC, Federation of Gynecology and Obstetrics (FIGO) stage IB.
View Article and Find Full Text PDFPatterns of care for vulvar cancer and insights from revised FIGO staging: a retrospective study.
World J Surg Oncol
December 2024
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Background: The objective of this study was to evaluate the clinicopathological characteristics and patterns of care among women diagnosed with vulvar malignancy at a tertiary care teaching institute. Additionally, the study aimed to analyse the implications of revised FIGO staging system on stage shift and patient outcomes.
Methods: A retrospective observational study was conducted, wherein hospital records of biopsy-proven cases of vulvar cancers managed over a period of 10 years were comprehensively reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!